JenaValve Technology Closes $50 Million Financing

GIMV

Equity Round led by Bain Capital Life Sciences

IRVINE, Calif. (February 5, 2020) – JenaValve Technology, Inc., developer and manufacturer of the
JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of
aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital
Life Sciences. Additional participants in the financing included existing investors Andera Partners, Gimv,
Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. The Company
also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the
JenaValve Board of Directors.

“We are pleased to complete this financing led by new investor Bain Capital Life Sciences, a wellrespected name in healthcare, as well as strong participation from our existing venture investors,” said John Kilcoyne, JenaValve’s Chief Executive Officer. “This announcement comes on the heels of receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), which
allows for priority review of our Align Clinical Trial for the treatment of symptomatic, severe aortic
regurgitation (AR) and AR-dominant mixed aortic valve disease. Our TAVR system is differentiated in
that no other transcatheter valve device has FDA approval for patients suffering from severe AR who are
at high risk for surgery, which we believe is a multi-billion-dollar market opportunity. This financing
supports our ongoing clinical program and plans to file for U.S. Humanitarian Device Exemption (HDE)
approval in the second half of 2020.”

JenaValve is conducting a global multicenter clinical program for the treatment of patients with severe
AR and AR-dominant mixed aortic valve disease who are at high risk for surgery. Following completion
of the HDE portion of the trial, patient enrollment will continue in support of submitting a Premarket
Approval (PMA) application to the FDA under the Breakthrough Device program. The Company also
anticipates filing the JenaValve® for CE mark approval for both aortic stenosis and aortic regurgitation in
the second half of 2020.
“We welcome Dr. Hack to our Board and look forward to Bain Capital’s contribution to governance and
strategy,” added Mr. Kilcoyne. “Andrew’s industry knowledge and experience, as well as his success as
an institutional investor and chief financial officer will add valuable perspectives to our Board.”
Dr. Hack commented, “I’m delighted to join the JenaValve Board as the Company works to gain approval
for a solution to a significant unmet medical need. JenaValve’s focus on advancing a breakthrough
technology with the ability to improve patient lives embodies the characteristics we seek at Bain Capital
Life Sciences. We are committed to providing both financial assistance and oversight in support of
JenaValve’s success.”

Dr. Hack has served as a Managing Director at Bain Capital Life Sciences since 2019. He previously
served as Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) and as a healthcare portfolio
manager at Millennium Management. Prior to that, he was a securities analyst at a number of healthcare focused hedge funds and investment banks. Dr. Hack received an MD and a PhD in molecular genetics
and cell biology from the University of Chicago.

About the JenaValve Transfemoral TAVR System
The JenaValve Pericardial TAVR System consists of a bioprosthesis comprised of a self-expanding nitinol
stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques.
The TAVR System is available in three sizes to treat a broad range of aortic annulus diameters.
The JenaValve Pericardial TAVR System is an investigational device, and is not available for sale in the
United States or internationally.

About Bain Capital Life Sciences
Bain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical,
specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies
globally. The team focuses on companies that both drive medical innovation across the value chain and
enable that innovation to improve the lives of patients with unmet medical needs. Since 1984, Bain
Capital has developed global reach, deep expertise and a proven track record in life sciences industries
across its Private Equity, Credit, Public Equity and Venture business units. Bain Capital Life Sciences
builds on the differentiated skillset and enables the firm to pursue opportunities created by several longterm trends in healthcare.

About JenaValve
JenaValve Technology, Inc., with locations in Irvine, Calif., Leeds, U.K. and Munich, Germany, develops
and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from
aortic valve disease. The Company is in clinical development of its next-generation transfemoral TAVR
system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic
regurgitation. In addition to Bain Capital Life Sciences, JenaValve is backed by European and Asian
investors, including Andera Partners (formerly Edmond de Rothschild Investment Partners), Gimv
(Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI
Partners. Additional information is available at www.jenavalve.com.
###
Investor and Media Contact:
Matt Clawson
W2Opure
(949) 370-8500
mclawson@w2ogroup.com

Categories: News

Tags:

JenaValve Technology Closes $50 Million Financing

GIMV

IRVINE, Calif. (February 5, 2020) – JenaValve Technology, Inc., developer and manufacturer of the
JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of
aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital
Life Sciences. Additional participants in the financing included existing investors Andera Partners, Gimv,
Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. The Company
also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the
JenaValve Board of Directors.

“We are pleased to complete this financing led by new investor Bain Capital Life Sciences, a wellrespected name in healthcare, as well as strong participation from our existing venture investors,” said John Kilcoyne, JenaValve’s Chief Executive Officer. “This announcement comes on the heels of receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), which
allows for priority review of our Align Clinical Trial for the treatment of symptomatic, severe aortic
regurgitation (AR) and AR-dominant mixed aortic valve disease. Our TAVR system is differentiated in
that no other transcatheter valve device has FDA approval for patients suffering from severe AR who are
at high risk for surgery, which we believe is a multi-billion-dollar market opportunity. This financing
supports our ongoing clinical program and plans to file for U.S. Humanitarian Device Exemption (HDE)
approval in the second half of 2020.”

JenaValve is conducting a global multicenter clinical program for the treatment of patients with severe
AR and AR-dominant mixed aortic valve disease who are at high risk for surgery. Following completion
of the HDE portion of the trial, patient enrollment will continue in support of submitting a Premarket
Approval (PMA) application to the FDA under the Breakthrough Device program. The Company also
anticipates filing the JenaValve® for CE mark approval for both aortic stenosis and aortic regurgitation in
the second half of 2020.

“We welcome Dr. Hack to our Board and look forward to Bain Capital’s contribution to governance and
strategy,” added Mr. Kilcoyne. “Andrew’s industry knowledge and experience, as well as his success as
an institutional investor and chief financial officer will add valuable perspectives to our Board.”
Dr. Hack commented, “I’m delighted to join the JenaValve Board as the Company works to gain approval
for a solution to a significant unmet medical need. JenaValve’s focus on advancing a breakthrough
technology with the ability to improve patient lives embodies the characteristics we seek at Bain Capital
Life Sciences. We are committed to providing both financial assistance and oversight in support of
JenaValve’s success.”

Dr. Hack has served as a Managing Director at Bain Capital Life Sciences since 2019. He previously
served as Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) and as a healthcare portfolio
manager at Millennium Management. Prior to that, he was a securities analyst at a number of healthcarefocused hedge funds and investment banks. Dr. Hack received an MD and a PhD in molecular genetics
and cell biology from the University of Chicago.

About the JenaValve Transfemoral TAVR System
The JenaValve Pericardial TAVR System consists of a bioprosthesis comprised of a self-expanding nitinol
stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques.
The TAVR System is available in three sizes to treat a broad range of aortic annulus diameters.
The JenaValve Pericardial TAVR System is an investigational device, and is not available for sale in the
United States or internationally.

About Bain Capital Life Sciences
Bain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical,
specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies
globally. The team focuses on companies that both drive medical innovation across the value chain and
enable that innovation to improve the lives of patients with unmet medical needs. Since 1984, Bain
Capital has developed global reach, deep expertise and a proven track record in life sciences industries
across its Private Equity, Credit, Public Equity and Venture business units. Bain Capital Life Sciences
builds on the differentiated skillset and enables the firm to pursue opportunities created by several longterm trends in healthcare.

About JenaValve
JenaValve Technology, Inc., with locations in Irvine, Calif., Leeds, U.K. and Munich, Germany, develops
and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from
aortic valve disease. The Company is in clinical development of its next-generation transfemoral TAVR
system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic
regurgitation. In addition to Bain Capital Life Sciences, JenaValve is backed by European and Asian
investors, including Andera Partners (formerly Edmond de Rothschild Investment Partners), Gimv
(Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI
Partners. Additional information is available at www.jenavalve.com.

Investor and Media Contact:
Matt Clawson
W2Opure
(949) 370-8500
mclawson@w2ogroup.com

Categories: News

Tags:

Hg invests in Intelerad Medical Systems, accelerating growth of best-in-class enterprise medical imaging solutions provider

HG Capital

  • Transaction will reinforce Hg’s focus on healthcare technology, with over $1bn invested to date in the sector globally;
  • Intelerad will look to use this new investment and expertise to maximize client business and health outcomes through innovation and operational excellence.

London, U.K. and Montreal, Canada, 23 January 2020

Hg, the specialist private equity investor focused on software and service businesses, today announces that it has finalized an agreement for an investment in Intelerad Medical Systems™ (“Intelerad”), a leading global provider of medical imaging software and enterprise workflow solutions. The terms of the transaction are not disclosed. The transaction is expected to close in the first quarter of 2020, following satisfaction of customary regulatory approvals.

Founded in 1999, Intelerad is a medical imaging software provider that specialises in diagnostic viewing, reporting and collaboration solutions for radiologists. Headquartered in Montreal (CA), Intelerad has over 400 employees located in various offices in Canada, the United States, the United Kingdom, and Australia. The company serves over 300 healthcare organizations around the world, including radiology groups, imaging centers, clinics and reading groups, and has a strong and growing presence in hospital imaging departments. Intelerad was awarded Best in KLAS recognitions, ranking #1 for PACS Canada and #1 for PACS Asia/Oceania in the 2019 Best in KLAS: Global Software (Non-US) report.

Hg recognizes Intelerad’s leading role in supporting radiologists globally to deliver highly accurate diagnoses at optimum productivity. The business is a key enabler of healthcare delivery against a backdrop of increasing global demands, in radiology, for scalable and more efficient imaging, data management and workflow solutions. Intelerad is led by a highly-talented team who have developed powerful solutions for radiologists, offering both efficiency and a premium service that helps create superior outcomes for both patients and healthcare providers.

Healthcare technology is a core sector for Hg, with an investment focus on healthcare operations, core systems, life sciences digitization, interoperability and population health. Intelerad represents the 5th healthcare technology investment in Hg’s current portfolio, joining Rhapsody + Corepoint, a global leader in healthcare interoperability and data liquidity solutions; Allocate Software, a global provider of healthcare workforce and risk management software; Evaluate, which supplies mission-critical commercial information to the pharmaceutical industry globally; and Medifox, which provides software solutions to ambulatory care services, elderly care homes and therapists.

Hg’s investment will be made from the Hg Genesis 8 Fund and represents the firm’s first investment in Canada and second investment led by the New York office, since opening in 2019. The Hg team was led by Gero Wittemann, Hector Guinness, J-B Brian and David Issott.

Under the terms of the agreement, Hg will acquire Intelerad from Novacap’s TMT IV Fund, and its founders, management and employee shareholders who will all be re-investing into the business alongside Hg.

Paul Lepage, Chief Executive Officer at Intelerad, said:

“Partnering with Hg gives us access to a huge pool of knowledge in global healthcare technology and the opportunity to significantly advance the company’s strategy. We are thrilled to continue making a difference in healthcare with such talented people. As well as welcoming our new investors, I also thank the Novacap team and our colleagues who all worked so hard to get us into this strong position, as well as our customers for their continued trust over the last 20 years. Looking forward to exciting times ahead.”

Gero Wittemann, Partner and co-lead of Hg’s New York team, commented:

“Intelerad has a winning platform that creates significant efficiencies for healthcare organizations, while adding true value to help radiologists and other physicians view, interpret and share medical images. We fully embrace Intelerad’s vision in making a sustainable difference in healthcare and it’s particularly exciting to join Paul and the team at this stage in the company’s journey. We will look to leverage our experience in healthcare technology and our operational experts to support the business strategy through innovation and operational excellence.”

Hg were advised on the investment by Tripletree, Bain, Marwood, EY and White & Case.

Categories: News

Tags:

Telemos Capital secures financing for Medeuropa, a leading european cancer care group

Telemos Capital

21.01.2020–Telemos Capital (“Telemos”) announces that its portfolio company MedEuropa, a leading European cancer care group, has successfully secured debt financing from Ardian. The senior facilities have been partially utilised as acquisition financing of MedEuropa’s first French acquisition and will continue to be used to support the company’s exciting buy-and-build strategy.

The financing is reflective of the strength of MedEuropa’s proposition and ability to execute on the organic and inorganic growth opportunities within the European cancer care market,with three radiotherapy centres already acquired since establishment.

Nils Hagerståland Dipesh Mahtani of Telemos said: “We are delighted to have secured debt financing for MedEuropa, which reinforces the strength of the strategy and execution capabilities of the management team. Ardian have shown themselves to be ideal partners to flexibly support MedEuropa as it pursues its ambitious buy-and-build strategy.

”Ralph Hefti, MedEuropa’s CEO, commented: “Ardian’s ability to offer a flexible solution to the Group’s requirements was key to this partnership. Ardian has been extremely responsive and creative and has set up financing that is very well suited to the way MedEuropa intends to move forward.”

Guillaume Chinardet, Head of Ardian Private Debt France, said: “We look forward to the long term cooperation with the MedEuropa management team and Telemos Capital, valuable partners with strong expertise in the European healthcare services market. We are convinced that MedEuropa will achieve further growth via strategic acquisitions in the fragmented European radiotherapy market.”

Press Contacts Telemos Capitalinfo@telemoscapital.com+44 (0)20 3906 6820

About MedEuropa

Founded in 2017, MedEuropa is committed to providing state of the art cancer treatment across Europe, with a strong focus on radiotherapy. MedEuropa seeks to partner with leading medical professionals, who share its vision of improving the provision and quality of cancer treatment. MedEuropa is pursuing an ambitious buy and build strategy, focusing on new partnership and acquisition opportunities across Europe.

Please visit www.medeuropa.org for more information.

About Telemos Capital

Telemos Capital, a London based investment firm founded in 2017,invests in private European businesses, with the aim of building great companies for the long term. Funded by family capital, it combines the flexibility and nimble decision-making of a family office with the active ownership and professionalism of private equity. Telemos looks to deploy €50m-€200m of equity per investment and seeks to acquire majority stakes in businesses with the potential for sustainable growth through international expansion, add-on acquisitions or operational improvements.

Please visit www.telemoscapital.com for more information.

 

Categories: News

Tags:

Ardian arranges a senior financing for Telemos Capital and Medeuropa’s acquisition of CCO Perpignan

Ardian

Paris, January 21st, 2020 – Ardian, a world leading private investment house, today announces the arrangement of a senior financing facility to support Telemos Capital and MedEuropa’s acquisition of CCO Perpignan. The financing package also includes a committed acquisition facility to finance future build-ups.

MedEuropa is a European cancer care company with a strong focus on radiotherapy. Radiotherapy is one of the most commonly used therapies for cancer treatment and consists in the use of high doses of radiation to eliminate cancer cells and shrink tumors. It can be used as a standalone oncology treatment or in combination with other cancer treatments such as surgery or chemotherapy.

Headquartered in Switzerland, the MedEuropa platform was founded in 2017 by Telemos Capital. The network was initially created through the acquisition of two radiotherapy centers in Germany in January 2019 (Krefeld and Hannover, the leading providers of Gamma Knife treatments, a specialized application of radiotherapy for complex brain tumors) and is to be further enlarged through the acquisition of CCO Perpignan, a radiotherapy center in the South of France.

The combination of all three entities will form a Group operating a total of six treatment machines treating a total c. 2,900 patients per year. As has been the case with the German acquisitions, MedEuropa will continue to partner with the CCO Perpignan doctors, ensuring continuity of high-quality care for patients and referring physicians.

Guillaume Chinardet, Head of Ardian Private Debt France, said: “We look forward to the long term cooperation with the MedEuropa management team and Telemos Capital, valuable partners with strong expertise in the European healthcare services market. We are convinced that MedEuropa will achieve further growth via strategic acquisitions in the fragmented European radiotherapy market.”

Jean-David Ponsin, Managing Director at Ardian Private Debt, further added: ”We are pleased to support the Group in this new chapter of its growth journey and we are convinced that our financing solution will provide the Group with the flexibility to pursue its future development.”

Ralph Hefti, MedEuropa’s CEO, commented: “Ardian’s ability to offer a flexible solution to the Group’s requirements was key to this partnership. Ardian has been extremely responsive and creative and has set up financing that is perfectly suited to the way MedEuropa intends to move forward.”

Nils Hagerstål, Vice President at Telemos Capital concluded: ”MedEuropa is actively considering further acquisition opportunities in the radiotherapy market, with the aim of building a platform in Western Europe. This ambitious development strategy demands a solid yet flexible financing solution, which Ardian has successfully provided.”

ABOUT CCO PERPIGNAN

 The CCO Perpignan center is located in Perpignan, in the South of France. It focuses on radiotherapy treatments through the operation of linear accelerators, treating a total 1,800 patients. It also provides some chemotherapy treatments in a more limited manner. CCO Perpignan enjoys a strong local reputation in the Pyrenées-Orientales region, and is known for providing high quality treatments to patients.

ABOUT MEDEUROPA

 Founded in 2017, MedEuropa is committed to providing state of the art cancer treatment across Europe, with a strong focus on radiotherapy. MedEuropa seeks to partner with leading medical professionals, who share its vision of improving the provision and quality of cancer treatment.  MedEuropa is pursuing an ambitious buy and build strategy, focusing on new partnership and acquisition opportunities across Europe.

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$96bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 640 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 1,000 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.

ABOUT TELEMOS CAPITAL

Telemos Capital invests in private European businesses, with the aim of building great companies for the long term. Funded by family capital, it combines the flexibility and nimble decision-making of a family office with the active ownership and professionalism of private equity. Telemos looks to deploy €50m-€200m of equity per investment and seeks to acquire majority stakes in businesses with the potential for sustainable growth through international expansion, add-on acquisitions or operational improvements.

LIST OF PARTIES INVOLVED

MedEuropa: Ralph Hefti, Raffael Kabir
Telemos Capital: Philippe Jacobs, Jacob Polny, Nils Hagerstål, Dipesh Mahtani
Ardian Private Debt: Guillaume Chinardet, Jean-David Ponsin, Gabrielle Philip

Financing Legal Advisor (Telemos Capital): Willkie Farr & Gallagher – Paul Lombard, Mathilde de Wiljes
Financing Legal Advisor (Ardian): Allen & Overy – Jean-Christophe David, Marine Tarditi, Adrien Repiquet

PRESS CONTACTS

ARDIAN
Headland
VIKTOR TSVETANOV

Categories: News

Tags:

Ardian to acquire a stake in the Santé CIE Group alongside existing shareholders, HLD and UI Gestion

Ardian

Ardian will accompany the Santé Cie Group and its subsidiaries, Elivie and Asdia, in their international expansion and enlarging their expertise in the home medical assistance market

Paris, January 17, 2020 – Ardian, a world-leading private investment house, today announces that it has signed an agreement to acquire a majority stake in Santé Cie, a specialist in home medical assistance. Ardian will invest alongside HLD and UI Gestion, company shareholders since 2015, and the management team, to continue the consolidation of the French market and develop internationally.

With this investment, Ardian will enter the home medical assistance market. It offers the Group the opportunity to operate in a new, particularly attractive healthcare segment, while having a very positive social and societal impact. Santé Cie’s business addresses deep demographic, sociological and health challenges tied to an ageing population, an increasing prevalence of chronic illnesses, and a medical desertification in French rural areas.

Through its two operating networks, Elivie and Asdia, Santé Cie is among the most dynamic players in the home medical assistance sector in France. As a multi-specialist, it addresses the needs of patients in respiratory assistance, insulin therapy, perfusion, nutrition, post-operative care and wound treatment and healing. The company accompanies more than 150,000 patients annually and reported revenue of €240 million in 2019. It has nearly 1,700 employees and its 80 agencies offer services throughout France.

This transaction remains subject to antitrust approval and the opinion of the work council.

Larbi Hamidi, Chairman of Santé Cie: “This is a new impetus for our business. We’ll be able to actively contribute to consolidating the French market and launching our European expansion, but also investing in innovative solutions to improve the efficiency of care pathways in the face of new challenges posed by connected healthcare and telehealth.”

Jean-Bernard Lafonta, Chairman of HLD Europe, said: “We’re proud of Santé Cie’s journey since 2015 to have become one of the leading home medical assistance players in France. We’re delighted to continue our commitment alongside Santé Cie’s management to develop the business internationally and explore promising new segments such as dialysis at home.”

Olivier Jarrousse, Managing Partner of UI Gestion, added: “We’re very pleased with Santé Cie’s progress over the past 5 years and we wish to continue our active contribution to the Group’s development.”

Yann Bak, Managing Director in the Ardian Buyout team, said: ” We’re proud to enter Santé Cie’s share capital alongside existing shareholders and are confident that home medical assistance providers, by assisting patients and ensuring they are monitored by practitioners, have a role to play in the French healthcare value chain .”

Nicolas Darnaud, Managing Director in the Ardian Buyout team, added: “Santé Cie’s strong competitive advantages, its management, its scalable structure, its proven expansion and diversification capabilities, and its many growth options give it significant room for further growth in a fast-expanding market.”

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$96bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 640 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 1,000 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.Follow Ardian on Twitter @Ardian

ABOUT SANTE CIE

Created in 2016, Santé Cie is the third largest home healthcare provider in France, through its two operating networks Elivie and Asdia.
With the trust of healthcare professionals, the company supports nearly 150,000 home care patients, both children and adults, across France every day. It covers a wide range of therapeutic segments including perfusion, nutrition, insulin therapy, the treatment of Parkinson’s disease, respiratory assistance and wound treatment and healing.
By means of a medical prescription, the Elivie and Asdia teams set up all equipment required at home for the care of patients with chronic or acute illnesses. By ensuring the home care pathway, training and patient support and monitoring, the teams provide solutions to simplify and secure patient care at home, in constant contact with prescribers and in coordination with their entourage and all participants in the care chain (pharmacists, nurses, physiotherapists, etc.)
Santé Cie has nearly 1,700 employees across 80 agencies throughout France, through its Elivie and Asdia networks.

ABOUT HLD

Created in 2010 by Jean-Philippe Hecketsweiler, Jean-Bernard Lafonta and Philippe Donnet, HLD has experienced remarkable growth in the investment capital sector. The investment holding company now has 12 companies in France and Europe (including Tessi, Kiloutou, Coyote, Santé Cie and Rafaut), representing combined revenue of almost €2 billion and 17,000 employees. True to the wishes of its shareholders, which include many European entrepreneurs, including the Decaux, Dentressangle and Claude Bébéar families, HLD invests without any time constraints. This has enabled strong ties to be forged with portfolio company management, and HLD to support the long-term development of companies in Europe and internationally.
The HLD teams are currently present in Europe: Luxembourg, Paris, Milan and Zurich.

ABOUT UI GESTION

A historical investment capital player for 50 years, UI Gestion is an independent management company managing more than €650 million on behalf of leading institutional investors, entrepreneurs and Family Offices.

Independent since 2004, with a regional coverage since 2010 (Paris, Nantes, Rennes, Rheims, Strasbourg and Lille), UI Gestion specializes in developing SMEs and helps their management implement growth projects and buyout and growth transactions. With the UI Academy, management benefit from complementary tools to strengthen the strategic definition of their projects and operational implementation.

Over the past 15 years, UI Gestion has raised more than €1 billion across three investment platforms (regional, national, sector-based) and has supported more than 130 companies, primarily in the health care, agro-business and equipment manufacturing sectors.

LIST OF PARTIES INVOLVED

Ardian team: Yann Bak, Nicolas Darnaud, Nicolas Kassab, Maxime Debost
M&A Advisor: BNP Paribas (Sylvina Mayer, Marc Walbaum, Sammy Lamali, Clara Blandeau)
Commercial and strategic advisor: LEK (Arnaud Sergent, Serge Hovsepian, Leonore Bosch, Servane Perrot)
Financial DD: 8advisory (Christophe Delas, Christian Berling, Nicolas Bassi)
Legal and Tax Advisor: Latham & Watkins (Gaëtan Gianasso, Thimothée Brunello, Mayssa Sader, Xavier Renard, Yann Auregan)
CSR Advisor: Indefi (Emmanuel Parmentier, Charlotte Salmon)
IT Advisor: 8advisory IT (Jean-Christophe Fuzzati)
Digital Advisor: Singulier (Rémi Pesseguier, Diane Levy)HLD team: Jean-Bernard Lafonta, Maxence Gailliot, Julia Marc
UI Gestion team: Olivier Jarrousse, Sébastien Alauzet, Edouard Vilmer
M&A advisor to the seller: Rothschild (Laurent Baril, Robert Rozemulder)
Financial DD: Accuracy (Arnaud Lambert, Marie Madelpuech)
Legal Advisor: Weil, Gotshal & Manges (Alexandre Duguay, Pierre-Alexandre Khan, Come Wirz, Romain Ferla, Anne-Laila Abback, Cassandre Porgès, Timothée Buchet)

PRESS CONTACTS

Santé Cie
Severine Duhr
ARDIAN
Image 7
Anne-Charlotte Creac’h
Tel: 01 53 70 94 21
accreach@image7.fr
Flora Larger
Tel: 01 53 70 74 90
flarger@image7.fr

Categories: News

Tags:

Montagu to acquire the OEM business of RTI Surgical Holdings

Montagu

Montagu Private Equity (“Montagu”), a leading European private equity firm, announces that it has agreed to acquire the OEM, sports and reconstructive surgery implants divisions of RTI Surgical Holdings (the “OEM business”).

RTI’s OEM business designs, develops, manufactures and distributes biologic, metal and synthetic implants for a global customer base. Its implants are used in a variety of surgical procedures including orthopaedic, spine, sports medicine, general surgery and trauma.

RTI Surgical Holdings was established in the 1990s as a small tissue bank at the University of Florida. Since then, it has grown both organically and through acquisitions to become a leading surgical implants business that enjoys long-term relationships with blue-chip customers. Headquartered in Florida, US, the business has four manufacturing sites located across Germany and the US.

Guillaume Jabalot, Director at Montagu, said: “As a strong, resilient business that is well-positioned to capitalise on accelerated growth opportunities, RTI’s OEM business is an excellent fit for Montagu’s investment strategy. We look forward to working with Olivier and the team to support the business in this exciting next chapter of growth, maintaining its ethos of exceptional service and innovation”.

Olivier Visa, President of RTI’s OEM business, said: “We are thrilled about Montagu’s purchase of the OEM business. We have built a world-class design, development and manufacturing competency with demonstrated expertise across tissue, biologics and hardware with a tremendous team and a customer base of leading medical technology companies. We look forward to working with Montagu in driving the growth of the business and deepening the significant expertise and core competencies we have developed to serve more patients”.

The transaction is subject to approval from RTI Surgical Holdings’ shareholders, customary regulatory approvals and the satisfaction of customary closing conditions and is targeted to close in the first half of 2020.

This is Montagu’s second carve-out transaction announcement in four months. The firm recently completed its acquisition of Jane’s Group from IHS Markit in December 2019.

Weil, Gotshal & Manges LLP acted as legal advisors to Montagu.

Categories: News

Tags:

GHO Capital acquires Ardena, a leading CDMO providing early stage drug development and manufacturing for small-to-mid sized biopharma

Mentha Capital

Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, together with the existing management team has acquired Ardena, a specialist contract development and manufacturing organization (CDMO) focused on early phase drug development, from Mentha Capital.

Ardena is a multi-service CDMO, assisting small-to-mid sized biopharma with services spanning the full development life cycle. The Company offers a comprehensive ‘Make, Analyse, File’ model from drug substance and drug product manufacturing and bioanalytical services through to regulatory dossier development. Headquartered in Belgium, the company operates across several sites in the Netherlands, Sweden and Latvia.

With a strong reputation for quality and a flexible service delivery model, Ardena caters to a highly diversified base of over 300 customers throughout Europe, the US, Japan and Korea. A high science approach and broad drug development toolkit differentiate Ardena from peers as a comprehensive multi-service pan-European platform.

With extensive sectoral expertise and network in the global biopharma industry, the GHO team will support management in accelerating Ardena’s plan to enable customers to take a molecule from ‘target to clinic’ with a single outsourced drug development service provider.

GHO plans to further strengthen Ardena’s broad service proposition through organic and inorganic opportunities, adding to both the Company’s offering and international footprint.

The Company is well-positioned to benefit from sector trends as an increasing number of biopharma companies outsource large parts of their early stage drug development work to highly specialised CDMOs.

Harry Christiaens, CEO of Ardena, commented: “With their deep expertise in the Pharma sector, we are excited now to partner with GHO as we continue our international growth. Ardena and GHO are fully committed to the science-led approach that delivers valuable solutions for our biopharma customers globally.”

The Partners at GHO Capital, commented: “We are delighted to have the opportunity to work with the Ardena team. Operating within a highly fragmented market, Ardena is the market leading platform from which to build a fully integrated early stage CDMO, serving Biopharma clients globally.”

Gijs Botman, Partner of Mentha Capital, commented: “Ardena has grown from a Ghent-based business to become a leading early-stage, multi-service CDMO in Western Europe. After successfully completing and integrating four acquisitions, the company is now ready for a new growth phase. We had a fantastic journey with the Ardena team, and we are confident that GHO Capital is the right partner to support their ambitions going forward.”

LinkedIn

Categories: News

Tags:

IK Investment Partners to sell CID Lines

ik-investment-partners

Ecolab Inc. announced today it reached an agreement to acquire the CID Lines group (“the Group”), from the IK VII Fund, advised by IK Investment Partners (IK), and the other shareholders. Completion of the transaction is subject to customary closing conditions, including approvals from applicable competition authorities. CID Lines is a hygiene and health solutions provider, principally focused on the animal health industry.

Founded in Belgium in 1989, CID Lines established itself as a leader in disinfectants for combatting infectious animal diseases. Today, the Group’s product range includes a variety of veterinary medicinal products as well as an extensive range of high-quality, branded biosecurity solutions for disinfection and cleaning procedures in farming environments.

Since partnering with CID Lines in January 2016, IK has supported the execution of a successful strategy that has realised continued strong growth. Through its expanding network, CID Lines serves customers across the globe and continues to enhance its base through its best-in-class commercial capabilities in combination with its excellent research & development and registration capabilities.

Remko Hilhorst, Managing Partner at IK Investment Partners and advisor to the IK VII Fund, commented: “CID Lines has made tremendous progress since we first partnered with them in 2016, cementing their position as a leader in the increasingly important market for biosecurity and immunity products that support reduced use of antibiotics in farm animals. We are grateful to have worked with such a dedicated team of professionals at CID Lines to help the business successfully expand its reach and product range. We wish them every success in the future and look forward to seeing how the Company develops.”

Koen Brutsaert, founder and CEO at CID Lines commented: “CID Lines showed excellent growth the last three years. The drivers behind this growth were continued investments in new products, registrations and our salesforce.  IK has been very supportive of these investments in our growth, and we would like to thank them for this support.”

For further questions, please contact:

IK Investment Partners
Remko Hilhorst, Managing Partner
+31 208 909210

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €10 billion of capital and invested in over 130 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

About CID Lines
Founded in Belgium in 1989, CID established itself as a leader in disinfectants for combatting infectious animal diseases. Today, the Group’s product range includes a variety of veterinary medicinal products as well as an extensive range of high-quality, branded biosecurity solutions for disinfection and cleaning procedures in farming environments.

Categories: News

Tags:

EQT invests in Asia based Health Management International

eqt

  • EQT Mid Market Asia invests in Health Management International, a reputable private healthcare provider with regional presence in Singapore, Malaysia and Indonesia
  • EQT will support Health Management International in realizing its full potential while scaling the Company’s platform in the region, organically and by exploring potential future acquisition opportunities
  • Health Management International was delisted from the Singapore Exchange on 24 December 2019

The EQT Mid Market Asia III fund (“EQT Mid Market Asia” or “EQT”) today announced its investment in Health Management International Ltd (“HMI” or the “Company”).

Founded in 1998, HMI is a regional private healthcare provider with presence in Singapore, Malaysia and Indonesia. The Company is headquartered in Singapore and is led by an experienced management team and has a board with vast experience in developing and growing healthcare businesses in the region. The Company’s two tertiary hospitals in Malaysia, Mahkota Medical Centre and Regency Specialist Hospital, which are known for their clinical quality and breadth of specialties and subspecialties, attract medical tourists from all around Southeast Asia and serve approximately 100,000 international patients per year.

HMI has a strategy of investing in its facilities and service offerings and has further expanded its healthcare platform through investments in the first private one-stop ambulatory care center in Singapore, StarMed Specialist Centre, and a General Practice clinic chain in Singapore, OneCare Medical.

EQT will support HMI in realizing the full potential of its existing healthcare businesses, while investing further in capacity and capabilities. EQT plans to back the Company’s accelerated growth trajectory, both organically and by exploring potential acquisition opportunities. HMI will also be able to leverage on EQT’s deep healthcare sector expertise, global network and vast experience rolling out digitalization initiatives.

The investment in HMI is in line with EQT’s thematic approach. HMI participates in the development, planning and implementation of sustainable strategies and engages in numerous community initiatives which include medical screenings and treatments, promoting wellness and preventive healthcare.

Chin Wei Jia, Group CEO at HMI, commented: “We are excited to welcome EQT as our new partner for the next chapter of HMI’s development. EQT made a strong impression on us from the outset with their strategic approach and deep experience across the various healthcare ecosystems globally. Together, we will be able to accelerate HMI’s growth by focusing on providing quality healthcare to become one of the leading private healthcare providers in the region.”

Brian Chang, Partner at EQT Partners, Investment Advisor to EQT Mid-Market Asia, commented: “HMI is a well-established healthcare group with a high-quality, talented team and a solid track record in the region. EQT is excited to partner with HMI and support the next chapter of its growth journey. Going forward, the joint focus will be on scaling HMI’s operations in the region with its differentiated, passionate and hands-on approach while continuing to deliver high quality healthcare to its customers.”

Contact
Brian Chang, Partner at EQT Partners, Investment Advisor to EQT Mid Market Asia, +65 6595 1830
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

About EQT
EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 41 billion in assets under management across 20 active funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on Twitter and LinkedIn

About Health Management International
HMI is a growing regional private healthcare provider with a presence in Singapore, Malaysia and Indonesia. HMI owns two tertiary hospitals in Malaysia, as well as a one-stop ambulatory care centre, healthcare training centre and a stake in a General Practice clinic chain in Singapore. HMI also has a network of representative offices in Indonesia, Malaysia and Singapore. HMI has more than 500,000 patients per annum, with over 200 practicing doctors and 1,800 staff.

More info: www.hmi.com.sg

Categories: News

Tags: